News in Brief
Pharmacology - Mar 28
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Pharmacology - Mar 27
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
wire - news in brief
« BACK
Pharmacology - Health - 28.03.2020
Pharmacology - Health - 27.03.2020
Pharmacology - Health - 27.03.2020
Health - Pharmacology - 26.03.2020 
"In a crisis like this, an antiviral drug could buy us some time"
Francesco Stellacci, a professor in EPFL's School of Engineering, discusses his research in the field of nanomedicine and how it could help us get past the coronavirus crisis.
Pharmacology - Business / Economics - 26.03.2020
Pharmacology - Health - 24.03.2020
Pharmacology - Health - 24.03.2020
Pharmacology - 23.03.2020
Pharmacology - Health - 20.03.2020
Pharmacology - Health - 19.03.2020
Pharmacology - Health - 18.03.2020
Pharmacology - Health - 17.03.2020
Health - Pharmacology - 13.03.2020 
Heading home with a rehab robot
Hands are our most important tools. Many stroke survivors struggle with a serious loss of function in their affected hand. ETH researchers are developing innovative solutions to help people in rehabilitation - and in everyday life. Hands are our most important tools. Many stroke survivors struggle with a serious loss of motor function in their affected hand.
Health - Pharmacology - 13.03.2020 
"We take rehabilitation to also mean inclusion."
ETH Zurich aims to step up rehabilitation research and education with the Rehab Initiative. But how are the needs of people with disabilities best met' To discuss the issues, we hosted a roundtable with a physician, a person with a disability and a researcher.
Health - Pharmacology - 11.03.2020
Pharmacology - Health - 03.03.2020
Pharmacology - Business / Economics - 02.03.2020
Health - Pharmacology - 27.02.2020
Pharmacology - Health - 25.02.2020
Pharmacology - Health - 24.02.2020
Pharmacology - Health - 17.02.2020
Pharmacology - Health - 11.02.2020
Health - Pharmacology - 05.02.2020
Pharmacology - Health - 31.01.2020
Pharmacology - Business / Economics - 31.01.2020
Pharmacology - Health - 29.01.2020 
& Development for Parasitic Worm Infections Lags Behind
Neglected tropical diseases (NTDs) are a group of mainly chronic infectious diseases that affect more than a billion people in tropical and subtropical countries.
Pharmacology - Business / Economics - 29.01.2020
Health - Pharmacology - 28.01.2020 
The universities of Bern and Zurich offer continuing education in gender-specific medicine
There is increasing evidence that health behavior and disease manifestation differ substantially between women and men.
Pharmacology - Health - 27.01.2020
Pharmacology - 22.01.2020
Pharmacology - Health - 21.01.2020
Pharmacology - Health - 20.01.2020
Health - Pharmacology - 15.01.2020
Health - Pharmacology - 09.01.2020 
One out of every two transplant recipients at risk of infection
Swiss researchers, including UNIGE, show that 50% of transplant recipients develop severe infections within a year of the operation, which can lead to death.
Pharmacology - Health - 09.01.2020
Pharmacology - Health - 06.01.2020
Pharmacology - 06.01.2020
Pharmacology - Health - 16.12.2019
Pharmacology - Health - 16.12.2019
Pharmacology - Health - 13.12.2019
Pharmacology - Health - 13.12.2019
Pharmacology - Health - 12.12.2019
Pharmacology - Health - 11.12.2019
Health - Pharmacology - 11.12.2019
Health - Pharmacology - 10.12.2019
Pharmacology - Health - 09.12.2019
Health - Pharmacology - 09.12.2019
Pharmacology - Health - 08.12.2019
Pharmacology - Health - 06.12.2019
Pharmacology - Health - 05.12.2019
Pharmacology
Results 1 - 50 of 1371.
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Patients & Caregivers Healthcare Professionals Society & ESG Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipo
Patients & Caregivers Healthcare Professionals Society & ESG Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipo
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
Patients & Caregivers Healthcare Professionals Society & ESG EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is
Patients & Caregivers Healthcare Professionals Society & ESG EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is
Francesco Stellacci, a professor in EPFL's School of Engineering, discusses his research in the field of nanomedicine and how it could help us get past the coronavirus crisis.
Zolgensma data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
Patients & Caregivers Healthcare Professionals Society & ESG Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma (onasemnogene abeparvovec-xioi) soon after birth
Patients & Caregivers Healthcare Professionals Society & ESG Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma (onasemnogene abeparvovec-xioi) soon after birth
Hands are our most important tools. Many stroke survivors struggle with a serious loss of function in their affected hand. ETH researchers are developing innovative solutions to help people in rehabilitation - and in everyday life. Hands are our most important tools. Many stroke survivors struggle with a serious loss of motor function in their affected hand.
ETH Zurich aims to step up rehabilitation research and education with the Rehab Initiative. But how are the needs of people with disabilities best met' To discuss the issues, we hosted a roundtable with a physician, a person with a disability and a researcher.
COVID-19: IRB receives EU emergency research funding
Following the publication of a ¤10 million call in January, the European Commission has secured an additional ¤37.5 million for urgently needed research on COVID-19 vaccine development, treatment and diagnostics.
Following the publication of a ¤10 million call in January, the European Commission has secured an additional ¤37.5 million for urgently needed research on COVID-19 vaccine development, treatment and diagnostics.
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Patients & Caregivers Healthcare Professionals Society & ESG FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping
Patients & Caregivers Healthcare Professionals Society & ESG FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping
Countering therapy resistance in colorectal cancer - News
A new treatment modality for colorectal cancers that do not respond to standard chemotherapy has been identified by Tatiana Petrova of the Lausanne Branch of the Ludwig Institute for Cancer Research and Michele De Palma of the EPFL. Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality.
A new treatment modality for colorectal cancers that do not respond to standard chemotherapy has been identified by Tatiana Petrova of the Lausanne Branch of the Ludwig Institute for Cancer Research and Michele De Palma of the EPFL. Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality.
Neglected tropical diseases (NTDs) are a group of mainly chronic infectious diseases that affect more than a billion people in tropical and subtropical countries.
There is increasing evidence that health behavior and disease manifestation differ substantially between women and men.
Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Fo
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Fo
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or
Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or
Novartis announces EU approval of Mayzent (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
Patients & Caregivers Healthcare Professionals Society & ESG Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple s
Patients & Caregivers Healthcare Professionals Society & ESG Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple s
Genome editing at the crossroads of scandal and cure
Genetic modification of babies in China one year ago was universally condemned. At the same time, CRISPR treatments are on their way into our clinics.
Genetic modification of babies in China one year ago was universally condemned. At the same time, CRISPR treatments are on their way into our clinics.
Swiss researchers, including UNIGE, show that 50% of transplant recipients develop severe infections within a year of the operation, which can lead to death.
Novartis ligelizumab (QGE031) more effective than Xolair at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria
Patients & Caregivers Healthcare Professionals Society & ESG Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly hig
Patients & Caregivers Healthcare Professionals Society & ESG Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly hig
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
Patients & Caregivers Healthcare Professionals Society & ESG Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipipra
Patients & Caregivers Healthcare Professionals Society & ESG Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipipra
Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc
All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.
All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.
Novartis receives positive CHMP opinion for Beovu (brolucizumab) for the treatment of wet AMD
Patients & Caregivers Healthcare Professionals Society & ESG In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one 1
Patients & Caregivers Healthcare Professionals Society & ESG In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one 1
Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma
Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).
Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s
APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen
Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr
Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr
Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Roche receives CE Mark for its Accu-Chek SugarView app
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
News in Brief
Pharmacology - Mar 28
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Pharmacology - Mar 27
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum